These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30651332)

  • 1. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.
    Caragher SP; Shireman JM; Huang M; Miska J; Atashi F; Baisiwala S; Hong Park C; Saathoff MR; Warnke L; Xiao T; Lesniak MS; James CD; Meltzer H; Tryba AK; Ahmed AU
    J Neurosci; 2019 Mar; 39(11):1982-1993. PubMed ID: 30651332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells.
    Li Y; Wang W; Wang F; Wu Q; Li W; Zhong X; Tian K; Zeng T; Gao L; Liu Y; Li S; Jiang X; Du G; Zhou Y
    J Mol Cell Biol; 2017 Aug; 9(4):302-314. PubMed ID: 28486630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
    Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5.
    Jeon HM; Oh YT; Shin YJ; Chang N; Kim D; Woo D; Yeup Y; Joo KM; Jo H; Yang H; Lee JK; Kang W; Sa J; Lee WJ; Hale J; Lathia JD; Purow B; Park MJ; Park JB; Nam DH; Lee J
    Neoplasia; 2023 May; 39():100894. PubMed ID: 36972629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.
    Weissenrieder JS; Reed JL; Green MV; Moldovan GL; Koubek EJ; Neighbors JD; Hohl RJ
    Pharmacology; 2020; 105(1-2):19-27. PubMed ID: 31645049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop.
    Wang Y; Wang X; Wang K; Qi J; Zhang Y; Wang X; Zhang L; Zhou Y; Gu L; Yu R; Zhou X
    J Exp Clin Cancer Res; 2023 Jul; 42(1):161. PubMed ID: 37415171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma.
    Li J; Zhu S; Kozono D; Ng K; Futalan D; Shen Y; Akers JC; Steed T; Kushwaha D; Schlabach M; Carter BS; Kwon CH; Furnari F; Cavenee W; Elledge S; Chen CC
    Oncotarget; 2014 Feb; 5(4):882-93. PubMed ID: 24658464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo.
    Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A
    Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.
    He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
    Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.
    D'Alessio A; Proietti G; Lama G; Biamonte F; Lauriola L; Moscato U; Vescovi A; Mangiola A; Angelucci C; Sica G
    Oncotarget; 2016 Nov; 7(48):78541-78556. PubMed ID: 27705944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eva1 Maintains the Stem-like Character of Glioblastoma-Initiating Cells by Activating the Noncanonical NF-κB Signaling Pathway.
    Ohtsu N; Nakatani Y; Yamashita D; Ohue S; Ohnishi T; Kondo T
    Cancer Res; 2016 Jan; 76(1):171-81. PubMed ID: 26677976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment.
    Agrawal R; Garg A; Benny Malgulwar P; Sharma V; Sarkar C; Kulshreshtha R
    Int J Cancer; 2018 May; 142(9):1817-1828. PubMed ID: 29226333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamines in glioblastoma: complex biology with therapeutic potential.
    Caragher SP; Hall RR; Ahsan R; Ahmed AU
    Neuro Oncol; 2018 Jul; 20(8):1014-1025. PubMed ID: 29126252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis.
    Joseph JV; Conroy S; Pavlov K; Sontakke P; Tomar T; Eggens-Meijer E; Balasubramaniyan V; Wagemakers M; den Dunnen WF; Kruyt FA
    Cancer Lett; 2015 Apr; 359(1):107-16. PubMed ID: 25592037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
    Nigim F; Cavanaugh J; Patel AP; Curry WT; Esaki S; Kasper EM; Chi AS; Louis DN; Martuza RL; Rabkin SD; Wakimoto H
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):710-22. PubMed ID: 26083570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.
    Lulli V; Buccarelli M; Martini M; Signore M; Biffoni M; Giannetti S; Morgante L; Marziali G; Ilari R; Pagliuca A; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Oncotarget; 2015 Nov; 6(35):37241-56. PubMed ID: 26437223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
    Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
    J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
    Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z
    Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.